This article was downloaded by: [University of California, San Diego] On: 12 June 2015, At: 04:38 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



# Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information: <u>http://www.tandfonline.com/loi/lcar20</u>

Synthesis of Cryptococcus neoformans Capsular Polysaccharide Structures. IV. Construction of Thioglycoside Donor Blocks and Their Subsequent Assembly

Mia Alpe<sup>a</sup>, Stefan Oscarson<sup>a</sup> & Pär Svahnberg<sup>a</sup>

<sup>a</sup> Department of Organic Chemistry, Arrhenius Laboratory, Stockholm University, Floor 6, Stockholm, S-106 91, Sweden Published online: 23 Feb 2007.

To cite this article: Mia Alpe, Stefan Oscarson & Pär Svahnberg (2003) Synthesis of Cryptococcus neoformans Capsular Polysaccharide Structures. IV. Construction of Thioglycoside Donor Blocks and Their Subsequent Assembly, Journal of Carbohydrate Chemistry, 22:7-8, 565-577, DOI: <u>10.1081/CAR-120026459</u>

To link to this article: http://dx.doi.org/10.1081/CAR-120026459

# PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <a href="http://www.tandfonline.com/page/terms-and-conditions">http://www.tandfonline.com/page/terms-and-conditions</a>

# Synthesis of *Cryptococcus neoformans* Capsular Polysaccharide Structures. IV. Construction of Thioglycoside Donor Blocks and Their Subsequent Assembly<sup>†</sup>

Mia Alpe, Stefan Oscarson,\* and Pär Svahnberg

Department of Organic Chemistry, Arrhenius Laboratory, Stockholm University, Sweden

#### ABSTRACT

Di- and trisaccharide thioglycoside building blocks, ethyl (2,3,4-tri-*O*-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)-3-*O*-allyl-4,6-di-*O*-benzyl-1-thio- $\alpha$ -D-mannopyranoside, ethyl (2,3,4-tri-*O*-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)-6-*O*-acetyl-3-*O*-allyl-4-*O*-benzyl-1-thio- $\alpha$ -D-mannopyranoside and ethyl (2,3,4-tri-*O*-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)]-3-*O*-allyl-6-*O*-benzyl-1-thio- $\alpha$ -D-mannopyranoside, corresponding to repetitive structures in the capsular polysaccharide (CPS) of *Cryptococcus neoformans* have been synthesised using silver triflate-promoted couplings between benzobromoxylose and properly protected mannose ethyl thioglycosides. The blocks contain an orthogonal allyl group in the 3-position of the mannose residue to allow continued formation of the (1  $\rightarrow$  3)-linked mannan backbone of the CPS. They have benzyl ethers as persistent protecting groups to facilitate access to the acetylated target structures. Assembly of the blocks employing DMTST as promoter in diethyl ether afforded in high yield and complete stereoselectivity penta- and hexasaccharide motifs from *C*.

<sup>†</sup>This paper is dedicated to Professor Gérard Descotes on the occasion of his 70<sup>th</sup> birthday. \*Correspondence: Stefan Oscarson, Department of Organic Chemistry, Arrhenius Laboratory Floor 6, Stockholm University, S-106 91 Stockholm, Sweden; E-mail: s.oscarson@organ.su.se.

565

DOI: 10.1081/CAR-120026459 Copyright © 2003 by Marcel Dekker, Inc. 0732-8303 (Print); 1532-2327 (Online) www.dekker.com *neoformans* serotype A–C. The latter were deallylated into new acceptors to allow synthesis of larger CPS-fragments.

*Key Words:* Convergent synthesis; Modular approach; Block synthesis; Glycoconjugate vaccines.

# **INTRODUCTION**

The fungi *Cryptococcus neoformans* is an opportunistic species causing severe diseases, i.e., meningitis, and death, especially in immunodeficient patients.<sup>[1,2]</sup> *C. neoformans* is divided into different serotypes, A–D, depending on the structure of the surface capsular polysaccharide (CPS), which is an important virulence factor.<sup>[3–5]</sup> The major polysaccharide is a heteropolymer made of an  $\alpha$ -D-(1  $\rightarrow$  3)-mannan backbone substituted with  $\beta$ -D-xylose residues in the 2 and 4-positions,  $\beta$ -D-glucuronic acid residues in the 2-positions and acetyl groups in the 6-positions.<sup>[6,7]</sup> The structures are more or less repeated in triads (Figure 1) and the different serotypes are defined by the amount and position of the xylose substituents (Table 1). The acetylation pattern is believed to be a major immunological determinant<sup>[7]</sup> but little else is known about the distribution of the 6-*O*-acetyl groups.

To investigate in more detail the nature of the immunological determinants and the biosynthesis of the *C. neoformans* CPS, well-defined synthetic oligosaccharides corresponding to fragments of the native CPS are in demand.

An attractive synthetic pathway to various CPS structures would be to combine diand trisaccharide thioglycoside building blocks, corresponding to the substituted mannose motifs, through the formation of the internal  $\alpha$ -(1  $\rightarrow$  3) linkages of the mannan backbone. With four disaccharide blocks (**I**, **II**, **IV** and **V**) and two trisaccharide blocks (**III** and **VI**) (Figure 2), all possible structures could theoretically be constructed. In initial attempts, however, this approach met with severe difficulties, regarding not only the synthesis of the building blocks but also their coupling.<sup>[8,9]</sup> Therefore another approach was employed to manufacture a number of *C. neoformans* CPS structures including tetrasaccharides.<sup>[10–12]</sup> In this, the mannan backbone was built up first and the xylose, glucuronic acid and acetyl residues were subsequently introduced. The same strategy has recently been used for the synthesis of a type A hexasaccharide structure.<sup>[13]</sup> Although so far successful, the synthesis of larger fragments



Figure 1. Schematic structure of deacetylated C. neoformans CPS.

Downloaded by [University of California, San Diego] at 04:38 12 June 2015

Xylp pos.	Serotype			
	А	В	С	D
2'	+	+	+	_
4′	_	_	+	_
4″	_	+	+	_

Table 1. Correlation between Xylp substitution and serotype.

using this technique would probably be limited because of the number of rather complex reactions involved on large structures. Thus, the block approach has therefore always been pursued. The successful formation and subsequent assembly of xylose-containing di- and trisaccharide building blocks (corresponding to structures I-III in Figure 2) are described herein.

### **RESULTS AND DISCUSSION**

First, to allow later formation of immunogenic glycoconjugates, the mannose acceptor **7** was constructed from the known peracetylated spacer-bearing glycoside **1**.<sup>[14]</sup> Thus, deacetylation of **1** ( $\rightarrow$ **2**), and subsequent 4,6-*O*-benzylidene acetal formation( $\rightarrow$ **3**), tin activation and regioselective 3-*O*-*p*-methoxybenzylation<sup>[15]</sup> ( $\rightarrow$ **4**), debenzylidenation ( $\rightarrow$ **5**), and benzylation ( $\rightarrow$ **6**) gave the key acceptor **7** in 27% overall yield after final removal of the *p*-methoxybenzyl group (Scheme 1).



R = Persistent protecting group, removable in the presence of acetyl groups  $R^2 =$  Temporary protecting group, removable in the presence of R and Ac groups

Figure 2. Desired thioglycoside building blocks.

Marcel Dekker, Inc. 270 Madison Avenue, New York, New York 10016



*Scheme 1. i*: NaOMe, MeOH, 99%; *ii*: PhCH(OMe)<sub>2</sub>, *p*-TsOH, MeCN, 70%; *iii*: a) Bu<sub>2</sub>SnO, MeOH, reflux; b) MBnCl, CsF, DMF, 64%; *iv*: HOAc (aq 70%), 70°C, 85%, *v*: BnBr, NaH, DMF, 88%; *vi*: DDQ, CH<sub>2</sub>Cl<sub>2</sub>/H<sub>2</sub>O, 0°C, 82%.

The building blocks were prepared from the thioglycoside derivative  $\mathbf{8}$ ,<sup>[16]</sup> which was regioselectively allylated in the 3-position using tin activation to give 9 (86%) (Scheme 2). Analogously to earlier syntheses,<sup>[10,11]</sup> silver triflate-promoted glycosylation of the latter with benzobromoxylose  $10^{[17]}$  gave the  $\beta$ -linked disaccharide 11 in excellent yield ( $\approx 95\%$ ). Since the continued use of acyl protecting groups was prohibited, due to the presence of acetyl substituents in the target compounds, the benzoyl groups in 11 were changed into benzyl groups by Zemplén deacylation ( $\rightarrow$ 12, <sup>1</sup>H NMR: 4.58 (d, 1H, J = 9 Hz, H-1')) followed by conventional benzylation ( $\rightarrow$ 13, 71%) from 9). This sequence could be performed on a large scale and gram quantities of disaccharide 13 were efficiently synthesised. To allow for the introduction of a 6-Oacetyl group and also to release torsional strains in the donor,<sup>[18]</sup> which could explain earlier low coupling yields,<sup>[8,9]</sup> the benzylidene acetal in **13** was opened under reductive conditions that normally yield mainly the 4-O-benzyl derivative (BH<sub>3</sub>-Me<sub>3</sub>N, AlCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>/Et<sub>2</sub>O).<sup>[19]</sup> Here, however, an inseparable 1:1-mixture of the 4-O- and the 6-O-benzyl derivatives 14a and 14b was obtained. Since both the 6-O-acetylated and benzylated derivates were desired this was not a disadvantage. Regioselective acetylation<sup>[20]</sup> of the obtained mixture afforded an easily separable mixture of the first thioglycoside donor 15 (35%, compare I in Figure 2) and 14b. The latter was subsequently benzylated to give the donor 16 (compare II in Figure 2) in 34% yield from 13. Notably, 14b also comprises the possibility to construct a trisaccharide donor block upon introduction of another xylose residue in the 4-position.



Scheme 2. *i*: a) Bu<sub>2</sub>SnO, MeOH, reflux; b) AllBr, CsF, DMF, 86%; *ii*: AgOTf, DTBP, CH<sub>2</sub>Cl<sub>2</sub>,  $-40^{\circ}$ C; *iii*: NaOMe, MeOH, 82%; *iv*: BnBr, NaH, DMF, 87%; *v*: BH<sub>3</sub>-Me<sub>3</sub>N, AlCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>/ Et<sub>2</sub>O, 0°C; *vi*: AcCl, collidine, CH<sub>2</sub>Cl<sub>2</sub>,  $-70^{\circ}$ C; *vii*: BnBr, NaH, DMF, 91%.



Scheme 3. *i*: NaCNBH<sub>3</sub>, HCl/Et<sub>2</sub>O, THF, 75%; *ii*: 10, AgOTf, DTBP, CH<sub>2</sub>Cl<sub>2</sub>,  $-40^{\circ}$ C; *iii*: NaOMe, MeOH, 65% over two steps; *iv*: BnBr, NaH, DMF, 61%.

However, a more efficient route to a trisaccharide building block (compare III in Figure 2) was to introduce the two xylose moieties at the same time (Scheme 3). Reductive opening of the benzylidene acetal in 9 yielded the 2,4-diol 17 (75%), which was glycosylated with donor 10 using silver triflate as promoter to yield the trisaccharide 18. Subsequent deacylation ( $\rightarrow$ 19), and benzylation, then afforded the desired block 20 in 40% yield from 17.



Scheme 4. i: DMTST, Et<sub>2</sub>O; ii: PdCl<sub>2</sub>, EtOH/MeOH.

#### Alpe, Oscarson, and Svahnberg

Assembly of the available blocks was then investigated. Dimethyl(methylthio)sulfonium triflate (DMTST)-promoted glycosylations in diethyl ether of acceptor **7** with disaccharide donors **15** and **16** gave the  $\alpha$ -linked trisaccharides **21** and **25**, respectively, in high yields (Scheme 4). Furthermore, after removal of the 3'-O-allyl group with PdCl<sub>2</sub>, both the obtained trisaccharide acceptors **22** and **26**, could be efficiently elongated by new stereoselective DMTST-promoted glycosylations proving the assembly concept. Glycosylation of acceptor **22** with donor **16** afforded pentasaccharide **23** (65%, 95% calculated on consumed acceptor), whereas coupling of acceptor **26** with donor **16** or trisaccharide donor **20** yielded pentasaccharide **27** (85%) and hexasaccharide **29** (85%), respectively. Subsequent deallylations then afforded new acceptors, the pentasaccharides **24** (80%) and **28** (62%) and hexasaccharide **30** (62%), into which glucuronic acid-containing building blocks can be introduced to produce structures corresponding to *Cryptococcus* serotypes A–C.

In conclusion, xylose-containing di- and trisaccharide motifs of the mannan backbone in the *C. neoformans* CPS have been efficiently synthesised as thioglycoside blocks, which were shown to be good donors in glycosylation reactions. This modular approach allows an iterative selective deprotection/glycosylation scheme to synthesize larger CPS oligosaccharide structures including acetylated target molecules. Access to similar glucuronic acid-containing building blocks should allow the synthesis of a large variety of CPS structures from the different serotypes found in *C. neoformans*.

## **EXPERIMENTAL**

**General methods.** TLC was carried out on Merck precoated 60  $F_{254}$  plates using UV-light and/or 8% aq sulfuric acid for visualization. Column chromatography was performed on silica gel (0.040–0.063 mm, Amicon). NMR spectra were recorded in CDCl<sub>3</sub> (internal Me<sub>4</sub>Si,  $\delta = 0.00$ ) at 25°C on a Varian 300 MHz or 400 MHz instrument. MALDI-TOF spectra were recorded on a Bruker Biflex III instrument using 2',4',6'-trihydroxyacetophenone trihydrate (THAP) as matrix. Organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> before evaporation, which was performed under reduced pressure.

**2-Azidoethyl 2,4,6-tri-O-benzyl-\alpha-D-mannopyranoside (7).** A solution of  $\mathbf{1}^{[14]}$  (1.26 g, 3.02 mmol) in MeOH (25 mL) was treated with a catalytic amount of 1 M methanolic NaOMe at rt overnight. Dowex 50 (H<sup>+</sup>) ion-exchange resin was added and the mixture was filtered, and concentrated to give 2-azidoethyl  $\alpha$ -D-mannopyranoside<sup>[21]</sup> (**2**, 742 mg, 99%) as a white solid; NMR data (CDCl<sub>3</sub>/CD<sub>3</sub>OD): <sup>13</sup>C,  $\delta$  50.8, 61.3, 66.5, 66.7, 71.0, 71.6, 72.9 and 100.4.  $\alpha,\alpha$ -Dimethoxytoluene (536 µL, 3.57 mmol) and *p*-toluenesulfonic acid (40 mg) were added to a solution of **2** (742 mg, 2.98 mmol) in MeCN (25 mL), and the resulting mixture was stirred at 60°C overnight. The mixture was neutralised with Et<sub>3</sub>N, concentrated and purified by silica gel chromatography (toluene–EtOAc 1:1) to yield 2-azidoethyl 4,6-*O*-benzylidene- $\alpha$ -D-mannopyranoside (**3**, 707 mg) as a mixture containing some unreacted starting material and also dibenzylidenated material, which was used without further purification in the next step; NMR data: <sup>13</sup>C,  $\delta$  50.5, 63.5, 66.7, 68.4, 68.7, 70.8, 78.7, 100.5, 102.3, 126.3–137.1. A solution of this mixture and dibutyltin oxide (626 mg, 2.52 mmol) in MeOH (50 mL) was refluxed for

570

#### Synthesis of Cryptococcus neoformans. IV

1 h, then concentrated and dried in vacuum. The residue was dissolved in DMF (50 mL) and p-methoxybenzyl chloride (341  $\mu$ L, 2.52 mmol) and CsF (414 mg, 2.72 mmol) were added, and the mixture was stirred at rt overnight. The mixture was diluted with toluene, washed twice with a sat aq KF solution, dried and concentrated. Silica gel chromatography (toluene-EtOAc 3:1) yielded 2-azidoethyl 4,6-O-benzylidene-3-O-pmethoxybenzyl- $\alpha$ -D-mannopyranoside (4, 612 mg, 45% from 2) as a syrup; NMR data:  $^{13}$ C,  $\delta$  50.7, 55.5, 63.9, 67.0, 69.0, 70.0, 73.1, 75.4, 78.8, 100.4, 101.9, 114.1–159.7. The position of the *p*-methoxybenzyl group is proven by the downfield shift of H-2 after acetylation of 4 [8 5.4 (dd, 1H, H-2)]. A solution of 4 (227 mg, 0.50 mmol) in 70% aq AcOH (10 mL) was heated at 70°C for 3 h, then concentrated and co-concentrated twice with toluene. Purification by silica gel chromatography (toluene-EtOAc 1:3) gave 2-azidoethyl 3-O-p-methoxybenzyl- $\alpha$ -D-mannopyranoside (5, 155 mg, 85%): NMR data: <sup>13</sup>C, δ 50.3, 55.1, 61.0, 64.7, 66.5, 67.7, 71.6, 72.7, 78.9, 99.7, 113.7-159.2. A 60% oil dispersion of sodium hydride (75 mg, 1.89 mmol) was washed once with dry light petroleum. DMF (3 mL) was added, and thereafter a solution of 5 (155 mg, 0.42 mmol) in DMF (4 mL) was added dropwise at 0°C. After 15 min, benzyl bromide (210 µL, 1.76 mmol) in DMF (3 mL) was added, and the solution was allowed to reach rt. MeOH (0.5 mL) was carefully added and the mixture was diluted with toluene, washed three times with H<sub>2</sub>O, dried and concentrated. Purification on a silica gel column (toluene-EtOAc 9:1) gave 2-azidoethyl 2,4,6-tri-O-benzyl-3-O-p-methoxybenzyl- $\alpha$ -D-mannopyranoside (6, 235 mg, 88%) as a syrup; NMR data: <sup>13</sup>C,  $\delta$  50.4, 55.2, 66.3, 69.2, 71.8, 72.0, 72.7, 73.2, 74.6 (2C), 74.9, 79.6, 98.1, 113.6–158.9. DDQ (173 mg, 0.76 mmol) was added at 0°C to a solution of **6** (374 mg, 0.58 mmol) in CH<sub>2</sub>Cl<sub>2</sub>:H<sub>2</sub>O (19:1, 20 mL). After stirring for 3 h, the mixture was washed twice with aq NaHCO3 and water. Concentration of the organic phase followed by silica gel chromatography (toluene–EtOAc 6:1) afforded 7 (248 mg, 82%);  $[\alpha]_{\rm D}$  + 22° (c 1.0, CHCl<sub>3</sub>); NMR data: <sup>13</sup>C, δ 50.4, 66.3, 69.0, 71.1, 71.5, 72.9, 73.3, 74.6, 76.3, 78.1, 97.1, 127.3-138.1.

Anal. Calcd for C<sub>29</sub>H<sub>33</sub>N<sub>3</sub>O<sub>6</sub>: C, 67.04; H, 6.40. Found: C, 66.85; H, 6.23.

Ethyl (2,3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)-6-O-acetyl-3-O-allyl-4-Obenzyl-1-thio-α-D-mannopyranoside (15) and ethyl (2,3,4-tri-O-benzyl-β-D-xylopyranosyl)- $(1 \rightarrow 2)$ -3-*O*-allyl-6-*O*-benzyl-1-thio- $\alpha$ -D-mannopyranoside (14b). A solution of  $\mathbf{8}^{[16]}$  (3.00 g, 9.60 mmol) and dibutyltin oxide (2.87 g, 11.53 mmol) in MeOH (200 mL) was refluxed for 1 h, then concentrated and dried in vacuum. The residue was dissolved in DMF (200 mL). Allyl bromide (979 µL, 11.57 mmol) and CsF (1.89 g, 12.44 mmol) were added, and the mixture was stirred at rt overnight. The reaction mixture was diluted with toluene and washed twice with a sat aq KF solution, dried and concentrated. Silica gel chromatography (toluene-EtOAc 3:1) yielded ethyl 3-O-allyl-4,6-O-benzylidene-1-thio- $\alpha$ -D-mannopyranoside (9, 2.92 g, 86%); NMR data: <sup>13</sup>C,  $\delta$ 14.9, 25.0, 63.8, 68.7, 71.5, 71.9, 75.4, 79.1, 84.2, 101.6, 117.6, 126.1-128.9, 134.4, 137.5. Silver triflate (5.47 g, 21.28 mmol) dissolved in dry toluene was added at  $-40^{\circ}$ C to a stirred solution of **9** (3.00 g, 8.51 mmol), **10**<sup>[17]</sup> (11.18 g, 21.28 mmol) and 2,6-ditert-butylpyridine (3.80 mL, 17.02 mmol) in distilled CH<sub>2</sub>Cl<sub>2</sub> (250 ml) containing crushed molecular sieves (4 Å). After 1 h, Et<sub>3</sub>N (2 mL) was added, and stirring was continued for 15 min. The mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>, filtered through a pad of

Copyright © 2003 by Marcel Dekker, Inc. All rights reserved

Celite, concentrated, and purified by silica gel chromatography (toluene–EtOAc 12:1) to give crude ethyl (2,3,4-tri-O-benzoyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)-3-O-allyl-4,6-Obenzylidene-1-thio- $\alpha$ -D-mannopyranoside (11). The crude disaccharide was dissolved in MeOH (250 mL), 1 M methanolic NaOMe (10 mL) was added, and the mixture was stirred for 4 h at rt. Dowex 50 ( $H^+$ ) ion-exchange resin was added, and the stirring was continued for 30 min. Filtration and concentration of the mixture followed by silica gel chromatography (toluene–EtOAc 1:3) gave ethyl ( $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)-3-Oallyl-4,6-O-benzylidene-1-thio- $\alpha$ -D-mannopyranoside (12, 3.37 g, 82% over two steps) as a white foam; NMR data: <sup>13</sup>C, δ 15.2, 25.9, 64.6, 65.5, 68.7, 69.7, 70.4, 73.2, 74.1, 74.8, 74.9, 79.8, 84.7, 101.1, 101.8, 118.9, 126.3-133.8, 134.1, 137.7; <sup>1</sup>H, δ 4.58 (d, 1 H,  $J_{1,2} = 9$  Hz, H-1'), 5.32 (s, 1 H, H-1). A 60% oil dispersion of sodium hydride (1.28 g, 31.85 mmol) was washed once with dry light petroleum. DMF (15 mL) was added followed by dropwise addition at 0°C of a solution of 12 (3.43 g, 7.08 mmol) in DMF (60 mL). After 15 min, benzyl bromide (3.54 mL, 29.73 mmol) in DMF (60 mL) was added and the solution was stirred for 1 h. MeOH (5 mL) was carefully added and the mixture was diluted with toluene and washed three times with H<sub>2</sub>O, dried and concentrated. Purification on a silica gel column (toluene-EtOAc 15:1) gave ethyl (2,3,4tri-O-benzyl- $\beta$ -D-xylopyranosyl)- $(1 \rightarrow 2)$ -3-O-allyl-4,6-O-benzylidene-1-thio- $\alpha$ -D-mannopyranoside (13, 4.67 g, 87%) as a syrup; NMR data: <sup>13</sup>C, δ 15.0, 25.6, 64.0, 64.5, 68.7, 70.9, 73.3, 74.1, 75.1, 75.5, 77.7, 77.8, 78.9, 81.3, 83.2, 83.7, 101.5, 103.0, 117.0, 126.0-128.8, 134.7, 137.5-138.6. MALDI-TOF MS: m/z calcd for C44H50NaO9S ([M + Na]<sup>+</sup>): 777.31. Found 776.72.

A solution of AlCl<sub>3</sub> (707 mg, 5.30 mmol) in diethyl ether (50 mL) was added dropwise during 30 min to a stirred mixture of 13 (1.00 g, 1.32 mmol), BH<sub>3</sub>-trimethylamine complex (3.86 g, 52.98 mmol) and 4 Å molecular sieves in CH<sub>2</sub>Cl<sub>2</sub>:diethyl ether (5:1, 120 mL) at 0°C. After 1 h, the mixture was filtered through a pad of Celite and 1M H<sub>2</sub>SO<sub>4</sub> was added to the filtrate, which then was stirred for 30 min. The phases were separated and the organic layer was washed with aq NaHCO<sub>3</sub> and H<sub>2</sub>O, dried and concentrated. A short silica gel column gave a mixture of 14a and 14b, which was acetylated at the primary hydroxyl group before further purification. The crude disaccharide mixture and sym-collidine (286 µL, 2.15 mmol) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and the solution was cooled to -70°C. Acetyl chloride (92 µL, 1.28 mmol) was added and the reaction was stirred for 10 min at  $-70^{\circ}$ C, then quenched with MeOH, and allowed to attain rt. Concentration of the mixture, followed by silica gel chromatography (toluene-EtOAc 15:1), afforded 15 (366 mg, 35% over two steps) together with 390 mg of ethyl (2,3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)-3-O-allyl-6-O-benzyl-1-thio- $\alpha$ -D-mannopyranoside (14b). 15:  $[\alpha]_D + 37^\circ$  (c 1.0, CHCl<sub>3</sub>); NMR data: <sup>13</sup>C, δ 15.0, 20.5, 25.7, 63.3, 64.1, 69.9, 70.5, 73.4, 74.0, 75.1, 75.2, 75.6, 76.9, 77.3, 78.4, 81.2, 82.5, 83.9, 103.5, 118.1, 127.6-128.9, 134.6, 138.0-138.8, 170.7; MALDI-TOF MS: m/z calcd for  $C_{46}H_{54}NaO_{10}S$  ([M + Na]<sup>+</sup>): 821.33. Found 820.91.

Anal. Calcd for C<sub>46</sub>H<sub>54</sub>O<sub>10</sub>S: C, 69.15; H, 6.81. Found: C, 68.91; H, 6.61.

Ethyl (2,3,4-tri-*O*-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)-3-*O*-allyl-4,6-di-*O*-benzyl-1-thio- $\alpha$ -D-mannopyranoside (16). A 60% oil dispersion of sodium hydride (41 mg, 1.03 mmol) was washed once with dry light petroleum. DMF (2 mL) was added, and a solution of 14b (390 mg, 0.52 mmol) in DMF (10 mL) was added dropwise at 0°C.

#### Synthesis of Cryptococcus neoformans. IV

Downloaded by [University of California, San Diego] at 04:38 12 June 2015

After 15 min, benzyl bromide (110 µL, 0.93 mmol) in DMF (5 mL) was added and the solution was stirred for 4 h. MeOH (1 mL) was carefully added and the mixture was diluted with toluene and washed three times with H<sub>2</sub>O, dried and concentrated. Purification on a silica gel column (toluene–EtOAc 15:1) gave **16** (378 mg, 34% over two steps) as a syrup;  $[\alpha]_D$  + 48° (*c* 1.0, CHCl<sub>3</sub>); NMR data: <sup>13</sup>C,  $\delta$  15.0, 25.5, 64.1, 69.4, 70.5, 71.9, 73.1, 73.4, 74.7, 74.9, 75.2, 75.5, 77.0, 77.3, 78.5, 81.0, 82.3, 84.0, 103.5, 117.7, 127.3–129.0, 134.8, 138.3–138.8; MALDI-TOF MS: *m/z* calcd for C<sub>51</sub>H<sub>58</sub> NaO<sub>9</sub>S ([M + Na]<sup>+</sup>): 869.37. Found 868.92.

Anal. Calcd for C<sub>51</sub>H<sub>58</sub>O<sub>9</sub>S: C, 72.31; H, 6.90. Found: C, 72.09; H, 7.11.

Ethyl (2,3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  4)-[(2,3,4-tri-O-benzyl- $\beta$ -Dxylopyranosyl)- $(1 \rightarrow 2)$ ]-3-*O*-allyl-6-*O*-benzyl-1-thio- $\alpha$ -D-mannopyranoside (20). A solution of 9 (832 mg, 2.36 mmol), NaCNBH<sub>3</sub> (1.56 g, 23.6 mmol) and 3 Å molecular sieves in distilled THF (100 mL) was stirred at rt under argon for 30 min. HCl in diethyl ether was added until pH = 1. After 30 min, the reaction mixture was filtered through a layer of Celite, concentrated and purified on silica gel (toluene-EtOAc, 4:1) to give ethyl 3-O-allyl-6-O-benzyl-1-thio-α-D-mannopyranoside (17, 624 mg, 1.76 mmol, 75%); NMR data: <sup>13</sup>C, δ 15.2, 25.4, 68.6, 69.8, 70.5, 71.1, 71.3, 74.0, 79.6, 84.0, 118.6, 128.1–128.8, 134.5, 138.2. Silver triflate (362 mg, 1.41 mmol) dissolved in dry toluene was added at  $-40^{\circ}$ C to a stirred solution of 17 (100 mg, 0.28 mmol), 10 (741 mg, 1.41 mmol) and 2,6-di-tert-butylpyridine (253 µL, 1.13 mmol) in distilled CH<sub>2</sub>Cl<sub>2</sub> (50 ml) containing crushed molecular sieves (4 Å). After 2h, Et<sub>3</sub>N (1 mL) was added and stirring was continued for 15 min. The mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>, filtered through a pad of Celite, concentrated, and purified by silica gel chromatography (toluene–EtOAc 10:1) to give crude ethyl (2,3,4-tri-O-benzoyl- $\beta$ -D-xylopyranosyl)- $(1 \rightarrow 4)$ -[(2,3,4-tri-O-benzoyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)]-3-O-allyl-6-O-benzyl-1thio- $\alpha$ -D-mannopyranoside (18). The crude trisaccharide was dissolved in MeOH (100 mL). 5 mL of 1 M methanolic NaOMe was added and the mixture was stirred for 2 h at rt. Dowex 50 ( $H^+$ ) ion-exchange resin was added, and stirring was continued for 30 min. Filtration and evaporation, followed by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>:MeOH 3:1), then gave ethyl ( $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  4)-[( $\beta$ -D-xylopyranosyl)- $(1 \rightarrow 2)$ ]-3-O-allyl-6-O-benzyl-1-thio- $\alpha$ -D-mannopyranoside (19, 113 mg, 65%) over two steps); NMR data: <sup>13</sup>C, δ 15.0, 25.8, 65.6, 65.7, 68.7, 69.5, 69.8, 71.4, 71.5, 72.1, 73.6, 73.7, 74.1, 75.3, 75.6, 76.4, 76.9, 82.7 (C-1), 102.2, 103.4 (C-1', 1"), 118.3, 128.1–133.1, 134.4, 137.6; MALDI-TOF MS: m/z calcd for C<sub>29</sub>H<sub>42</sub>NaO<sub>13</sub>S  $([M + Na]^{+})$ : 641.22. Found 640.91.

A solution of **19** (113 mg, 0.18 mmol) and BnBr (260 µL, 2.19 mmol) in dry DMF (10 mL) was added dropwise to a cold (0°C) suspension of NaH (110 mg, 2.75 mmol) in DMF (10 mL). The mixture was stirred at rt for 4 h before the addition of MeOH (2 mL). Toluene was added, and the mixture was washed with sat aq NaHCO<sub>3</sub> and water. The organic layer was dried, concentrated and purified by silica gel chromatography (toluene–EtOAc, 10:1) to give **20** (129 mg, 0.11 mmol, 61%);  $[\alpha]_D + 52^\circ$  (*c* 1.0, CHCl<sub>3</sub>); NMR data: <sup>13</sup>C,  $\delta$  15.0, 25.5, 63.7, 64.0, 68.9, 71.3, 71.9, 72.9, 73.1, 73.3, 74.7, 74.9, 75.5, 76.5, 76.7, 77.0, 77.5, 78.2, 81.1, 82.0, 82.3, 84.0, 84.2, 103.1, 103.3, 116.8, 127.3–129.0, 135.3, 138.2–138.9; MALDI-TOF MS: *m/z* calcd for C<sub>70</sub>H<sub>78</sub> NaO<sub>13</sub>S ([M + Na]<sup>+</sup>): 1181.51. Found 1180.95.

Anal. Calcd for C<sub>70</sub>H<sub>78</sub>O<sub>13</sub>S: C, 72.51; H, 6.78. Found: C, 72.30; H, 6.91.

2-Azidoethyl (2.3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)- $(1 \rightarrow 2)$ -(4,6-di-O-benzyl- $\alpha$ -D-mannopyranosyl)- $(1 \rightarrow 3)$ - $[(2,3,4-tri-O-benzyl-\beta-D-xylopyranosyl)-(1 \rightarrow 2)]-(6-O-benzyl-\beta-D-xylopyranosyl)-(1 \rightarrow 2)]-(6-O-benzyl-\beta-D-xylopyranos$ acetyl-4-*O*-benzyl- $\alpha$ -D-mannopyranosyl)-(1  $\rightarrow$  3)-2,4,6-tri-*O*-benzyl- $\alpha$ -D-mannopyranoside (24). A solution of 7 (102 mg, 0.20 mmol) and 15 (235 mg, 0.29 mmol) in dry diethyl ether (10 mL) containing powdered molecular sieves (4 Å) was stirred at rt in an argon atmosphere for 30 min. DMTST (203 mg, 0.78 mmol) was added to the mixture, and stirring was continued for 6 h. After neutralization with Et<sub>3</sub>N, the mixture was filtered through a pad of Celite and concentrated. The residue was purified on a silica gel column (toluene-EtOAc 6:1) to yield crude 2-azidoethyl (2,3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)- $(1 \rightarrow 2)$ -(6-O-acetyl-3-O-allyl-4-O-benzyl- $\alpha$ -D-mannopyranosyl)- $(1 \rightarrow 3)$ -(2,4,6-tri-O-benzyl- $\alpha$ -D-mannopyranoside) (21, 163 mg, 65%). PdCl<sub>2</sub> (60%, 3) mg, 9.8 µmol) was added to a solution of 21 (123 mg, 0.098 mmol) in EtOH:MeOH (1:1, 6 mL). The mixture was stirred for 7 h, then filtered through a pad of Celite, concentrated and purified on a silica gel column (toluene-EtOAc 5:1) to yield 2azidoethyl (2,3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)-(6-O-acetyl-4-O-benzyl- $\alpha$ -Dmannopyranosyl)- $(1 \rightarrow 3)$ -2,4,6-tri-O-benzyl- $\alpha$ -D-mannopyranoside (22, 71 mg, 60%); NMR data: <sup>13</sup>C, δ 20.8, 50.6, 63.7, 64.1, 66.8, 69.2, 70.0, 71.1, 72.6, 72.8, 73.6, 73.7, 74.6, 74.9, 75.0, 75.2, 75.8, 76.4, 77.5, 77.5, 78.9, 80.4, 81.3, 83.3, 98.1 (C-1), 100.5 (C-1'), 104.0 (C-1''), 126.9–138.9, 170.9; <sup>1</sup>H,  $\delta$  5.15 (H-1'). A solution of **22** (65 mg, 0.053 mmol) and 16 (68 mg, 0.080 mmol) in dry diethyl ether (5 mL) containing powdered molecular sieves (4 Å) was stirred at rt in an argon atmosphere for 30 min. DMTST (55 mg, 0.21 mmol) was added to the mixture, and the stirring was continued for 5 h. After neutralization with  $Et_3N$ , the mixture was filtered through a pad of Celite and concentrated. The residue was purified on a silica gel column (toluene-EtOAc 9:1) to yield 2-azidoethyl (2,3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)-(3-O-allyl-4,6-di-*O*-benzyl- $\alpha$ -D-mannopyranosyl)- $(1 \rightarrow 3)$ - $[(2,3,4-tri-O-benzyl-\beta-D-xylopyranosyl) (1 \rightarrow 2)$ ]-(6-*O*-acetyl-4-*O*-benzyl- $\alpha$ -D-mannopyranosyl)-(1  $\rightarrow$  3)-2,4,6-tri-*O*-benzyl- $\alpha$ -D-mannopyranoside [23, 69 mg, 65% (95% based on consumed acceptor)] together with 21 mg of unreacted 22; NMR data 23:  $^{13}$ C,  $\delta$  20.3, 50.2, 62.9–83.1, 97.4 (C-1), 99.8, 100.3 (C-1', 1"'), 103.4 (2C, C-1", 1""), 116.4, 126.4-128.5, 135.0, 137.6-139.1, 170.4. PdCl<sub>2</sub> (60%, 1 mg, 3.2  $\mu$ mol) was added to a solution of 23 (60 mg, 0.030 mmol) in EtOH:MeOH (1:1, 6 mL). The mixture was stirred for 5 h, filtered through a pad of Celite, concentrated and purified on a silica gel column (toluene-EtOAc 6:1) to yield **24** (47 mg, 80%);  $[\alpha]_{D}$  + 10° (*c* 1.0, CHCl<sub>3</sub>); NMR data: <sup>13</sup>C, 20.5, 50.4, 63.1– 83.2, 97.6 (C-1), 100.3, 100.7 (C-1', 1'''), 103.6, 103.9 (C-1",1"''), 126.6-139.2, 170.6; <sup>1</sup>H,  $\delta$  5.14, 5.28 (H-1', 1'''); MALDI-TOF MS: *m*/*z* calcd for C<sub>116</sub>H<sub>125</sub>N<sub>3</sub>NaO<sub>25</sub>  $([M + Na]^+)$ : 1982.85. Found 1983.05.

Anal. Calcd for C<sub>116</sub>H<sub>125</sub>N<sub>3</sub>O<sub>25</sub>: C, 71.04; H, 6.42. Found: C, 70.84; H, 6.62.

2-Azidoethyl (2,3,4-tri-*O*-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)-(4,6-di-*O*-benzyl- $\alpha$ -D-mannopyranosyl)-(1  $\rightarrow$  3)-2,4,6-tri-*O*-benzyl- $\alpha$ -D-mannopyranoside (26). A solution of 7 (44 mg, 0.085 mmol) and 16 (100 mg, 0.12 mmol) in dry diethyl ether (5 mL) containing powdered molecular sieves (4 Å) was stirred at rt in an argon atmosphere for 30 min. DMTST (87 mg, 0.34 mmol) was added to the mixture, and stirring was continued for 3 h. After neutralization with Et<sub>3</sub>N, the mixture was filtered through a pad of Celite and concentrated. The residue was purified on a silica gel column (toluene–EtOAc 12:1) to yield 2-azidoethyl (2,3,4-tri-*O*-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)-(3-*O*-allyl-4,6-di-*O*-benzyl- $\alpha$ -D-mannopyranosyl)-(1  $\rightarrow$  3)-2,4,6-tri-*O*-benzyl- $\alpha$ -D-mannopyranoside (25, 100)

mg, 91%); NMR data: <sup>13</sup>C, δ 50.4, 63.9–83.5, 97.8 (C-1), 99.9 (C-1'), 103.6 (C-1"), 117.2, 126.8–129.1, 135.1, 138.2–139.0. PdCl<sub>2</sub> (60%, 1 mg, 3.2 μmol) was added to a solution of **25** (41 mg, 0.031 mmol) in EtOH:MeOH (1:1, 6 mL). The mixture was stirred for 5 h, filtered through a pad of Celite, concentrated and purified on a silica gel column (toluene–EtOAc 9:1) to yield **26** (29 mg, 73%);  $[\alpha]_D$  + 33° (*c* 1.0, CHCl<sub>3</sub>); NMR data: <sup>13</sup>C, δ 50.4, 63.9, 66.6, 69.0, 69.4, 70.7, 72.2, 72.4, 72.5, 73.3, 73.3, 73.4, 74.4, 74.6, 74.7, 74.9, 75.5, 77.2, 77.5, 80.4, 80.7, 83.2, 97.9 (C-1), 100.5 (C-1'), 103.9 (C-1"), 126.8–128.7, 138.1–138.9; <sup>1</sup>H, δ 5.22 (H-1'); MALDI-TOF MS: *m/z* calcd for C<sub>75</sub>H<sub>81</sub>N<sub>3</sub>NaO<sub>15</sub> ([M + Na]<sup>+</sup>): 1286.56. Found 1286.17.

Anal. Calcd for C75H81N3O15: C, 71.24; H, 6.46. Found: C, 71.03; H, 6.67.

2-Azidoethyl (2,3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  2)-(4,6-di-O-benzyl- $\alpha$ -D-mannopyranosyl)- $(1 \rightarrow 3)$ - $[(2,3,4-tri-O-benzyl-\beta-D-xylopyranosyl)-(1 \rightarrow 2)]$ -(4,6-di-D-xylopyranosyl)- $(1 \rightarrow 2)$ -(4,6-di-D-xylopyranosyl)- $(1 \rightarrow 2)$ -(4,6-di-D-xylopyranosyl)- $(1 \rightarrow 2)$ - $(1 \rightarrow$ O-benzyl- $\alpha$ -D-mannopyranosyl)- $(1 \rightarrow 3)$ -2,4,6-tri-O-benzyl- $\alpha$ -D-mannopyranoside (28). A solution of 26 (76 mg, 0.060 mmol) and 16 (74 mg, 0.087 mmol) in dry diethyl ether (10 mL) containing powdered molecular sieves (4 Å) was stirred at rt in an argon atmosphere for 30 min. To the mixture was added DMTST (63 mg, 0.24 mmol) and the stirring was continued for 2 h. After neutralization with  $Et_3N$ , the mixture was filtered through a pad of Celite, and concentrated. The residue was purified on a silica gel column (toluene-EtOAc 9:1) to yield crude 2-azidoethyl (2,3,4tri-*O*-benzyl- $\beta$ -D-xylopyranosyl)- $(1 \rightarrow 2)$ -(3-*O*-allyl-4,6-di-*O*-benzyl- $\alpha$ -D-mannopyranosyl)- $(1 \rightarrow 3)$ -[(2,3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)- $(1 \rightarrow 2)$ ]-(4,6-di-O-benzyl- $\alpha$ -D-mannopyranosyl)-(1  $\rightarrow$  3)-2,4,6-tri-O-benzyl- $\alpha$ -D-mannopyranoside (27, 105 mg, 85%). PdCl<sub>2</sub> (60%, 1 mg, 3.2 µmol) was added to a solution of **27** (105 mg, 0.051 mmol) in EtOH:MeOH (1:1, 6 mL). The mixture was stirred for 5 h, filtered through a pad of Celite, concentrated and purified on a silica gel column (toluene-EtOAc 9:1) to yield **28** (64 mg, 62%);  $[\alpha]_{D}$  + 9° (c 1.0, CHCl<sub>3</sub>); NMR data: <sup>13</sup>C,  $\delta$  50.6, 63.4–83.5, 97.9 (C-1), 100.7, 100.8 (C-1', 1"'), 103.9, 104.1 (C-1", 1""), 126.4-128.7, 138.4-139.5; <sup>1</sup>H,  $\delta$  5.18, 5.28 (H-1', 1'''); MALDI-TOF MS: m/z calcd for C<sub>121</sub>H<sub>129</sub>N<sub>3</sub>NaO<sub>24</sub>  $([M + Na]^{+})$ : 2030.89. Found 2030.73.

Anal. Calcd for C<sub>121</sub>H<sub>129</sub>N<sub>3</sub>O<sub>24</sub>; C, 72.33; H, 6.47. Found: C, 72.19; H, 6.62.

2-Azidoethyl (2,3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  4)-[(2,3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)- $(1 \rightarrow 2)$ ]-(6-O-benzyl- $\alpha$ -D-mannopyranosyl)- $(1 \rightarrow 3)$ -[(2,3,4tri-O-benzyl- $\beta$ -D-xylopyranosyl)- $(1 \rightarrow 2)$ ]-(4,6-di-O-benzyl- $\alpha$ -D-mannopyranosyl)- $(1 \rightarrow 3)$ -2,4,6-tri-O-benzyl- $\alpha$ -D-mannopyranoside (30). A solution of 20 (33 mg, 29 µmol) and 26 (25 mg, 20 µmol) in dry diethyl ether (5 mL) containing powdered molecular sieves (4 Å) was stirred at rt in an argon atmosphere for 30 min. To the mixture was added DMTST (20 mg, 79 µmol), and stirring was continued for 30 min. After neutralization with  $Et_3N$ , the mixture was filtered through a pad of Celite and concentrated. The residue was purified on a silica gel column (toluene-EtOAc 10:1) to yield 2-azidoethyl (2,3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)-(1  $\rightarrow$  4)-[(2,3,4-tri-O-benzyl- $\beta$ -D-xylopyranosyl)- $(1 \rightarrow 2)$ ]- $(3-O-allyl-6-O-benzyl-\alpha-D-mannopyranosyl)-<math>(1 \rightarrow 3)$ - $[(2,3,4-tri-O-benzyl-\beta-D-xylopyranosyl)-(1 \rightarrow 2)]-(4,6-di-O-benzyl-\alpha-D-mannopyr$ anosyl)- $(1 \rightarrow 3)$ -2,4,6-tri-O-benzyl- $\alpha$ -D-mannopyranoside side (29, 39 mg, 17  $\mu$ mol, 85%); Selected NMR data: <sup>13</sup>C, δ 97.8 (C-1), 99.6, 100.2 (C-1', 1"'), 103.2, 103.3, 103.5 (C-1'', 1''''); MALDI-TOF MS: m/z calcd for  $C_{143}H_{153}N_3NaO_{28}$  ([M + Na]<sup>+</sup>): 2383.05, Found 2383.35. PdCl<sub>2</sub> (60%, 5 mg, 17 µmol) was added to a solution of 29 (18 mg, 7.6 µmol) in EtOH:MeOH (1:1, 4 mL). The mixture was stirred for 2 h, filtered through a pad of Celite, concentrated and purified on a silica gel column (toluene–EtOAc 10:1) to give **30** (11 mg, 62%);  $[\alpha]_D + 25^\circ$  (*c* 1.0, CHCl<sub>3</sub>); Selected NMR data: <sup>13</sup>C,  $\delta$  97.7 (C-1), 98.6, 100.2 (C-1', 1'''), 103.1, 103.4, 104.0 (C-1'', 1'''', 1''''); <sup>1</sup>H,  $\delta$  5.17, 5.29 (H-1', 1''').

Anal. Calcd for C<sub>140</sub>H<sub>149</sub>N<sub>3</sub>O<sub>28</sub>: C, 72.43; H, 6.47. Found: C, 72.20; H, 6.61.

## ACKNOWLEDGMENTS

Financial support from the Swedish Foundation for Strategic Research (the "Glycoconjugates in Biological Systems" program) and from the Swedish Natural Science Research Council are gratefully acknowledged.

#### REFERENCES

- Brummer, E. Human defences against *Cryptococcus neoformans*: an update. Mycopathologia 1999, 143, 121–125.
- 2. Cherniak, R.; Sundstrom, B.J. Polysaccharide antigens of the capsule of *Cryptococcus neoformans*. Infect. Immun. **1994**, 62, 1507–1512.
- 3. Fromtling, R.A.; Shadomy, H.J.; Jacobson, E.S. Decreased virulence in stable capsular mutants of *Cryptococcus neoformans*. Mycopathologia **1982**, *79*, 23–29.
- 4. Aberg, J.A.; Powderly, W.G. Cryptococcosis. Adv. Pharmacol. 1997, 37, 215-251.
- 5. Doering, T.L. How does Cryptococcus get its coat? Trends Microbiol. 2000, 8, 547–553.
- Bhattacharjee, A.K.; Bennet, J.E.; Glaudemans, C.P.J. Capsular polysaccharides of Cryptococcus neoformans. Rev. Infect. Dis. 1984, 6, 619–624.
- Belay, T.; Cherniak, R. Determination of antigen binding specificities of *Cryptococcus neoformans* factor sera by enzyme-linked immunosorbent assay. Infect. Immun. 1995, 63, 1810–1819.
- Olsson, L. Synthesis of oligosaccharide fragments from *Cryptococcus neoformans* polysaccharide capsule and preparation of glucuronic acid thioglycosides for βglucuronide synthesis. Licentiate thesis; Stockholm University, 1994.
- 9. Olsson, L. Synthesis of oligosaccharides related to the capsular polysaccharide of *Cryptococcus neoformans*. Doctoral thesis; Stockholm University, 1996.
- Garegg, P.J.; Olsson, L.; Oscarson, S. Synthesis of oligosaccharides corresponding to structures found in capsular polysaccharides of *Cryptococcus neoformans*. J. Carbohydr. Chem. **1993**, *12*, 955–967.
- Garegg, P.J.; Olsson, L.; Oscarson, S. Synthesis of oligosaccharides corresponding to structures found in capsular polysaccharides of *Cryptococcus neoformans*. Part 2. Bioorg. Med. Chem. **1996**, *4*, 1867–1871.
- Garegg, P.J.; Olsson, L.; Oscarson, S. Synthesis of oligosaccharides corresponding to structures found in capsular polysaccharides of *Cryptococcus neoformans*. Part 3. A regioselectively acetylated tetrasaccharide. J. Carbohydr. Chem. **1997**, *16*, 973– 981.

576

#### Synthesis of Cryptococcus neoformans. IV

- Zhang, J.; Kong, F. An efficient synthesis of a hexasaccharide—the repeating unit 13. of the exopolysaccharide from Cryptococcus neoformans servora A. Tetrahedron Lett. 2003, 44, 1839-1842.
- Chernyak, A.Y.; Sharma, G.V.M.; Kononov, L.O.; Krishna, P.R.; Levinsky, A.B.; 14. Kochetkov, N.K.; Rama Rao, A.V. 2-Azidoethyl glycosides: glycosides potentially useful for the preparation of neoglycoconjugates. Carbohydr. Res. 1992, 223, 303-309.
- Zegelaar-Jaarsveld, K.; Smits, S.A.W.; van der Marel, G.A.; van Boom, J.H. 15. Synthesis of a pentasaccharide corresponding to the repeating unit of the exopolysaccharide from Cryptococcus neoformans serovar D. Bioorg. Med. Chem. **1996**, *4*, 1819–1832.
- Garegg, P.J.; Kvarnström, I.; Niklasson, A.; Niklasson, G.; Svensson, S.C.T. Partial 16. substitution of thioglycosides by phase-transfer catalysed benzoylation and benzylation. J. Carbohydr. Chem. 1993, 12, 933-953.
- 17. Fletcher, H.G.; Hudson, C.S. 1,5-Anhydro-xylitol. J. Am. Chem. Soc. 1947, 69, 921-924.
- Andrews, C.W.; Rodebaugh, R.; Fraser-Reid, B. A solvation-assisted model for 18. estimating anomeric reactivity. Predicted versus observed trends in hydrolysis of *n*pentenyl glycosides. J. Org. Chem. 1996, 61, 5280-5289.
- 19. Ek, M.; Garegg, P.J.; Hultberg, H.; Oscarson, S. Reductive ring openings of carbohydrate benzylidene acetals using borane-trimethylamine and aluminium chloride. Regioselectivity and solvent dependence. J. Carbohydr. Chem. 1983, 2, 305-311.
- Ishihara, K.; Kurihara, H.; Yamamoto, H. An extremely simple, convenient, and 20. selective method for acetylating primary alcohols in the presence of secondary alcohols. J. Org. Chem. 1993, 58, 3791-3793.
- 21. Lindhorst, T.; Kötter, S.; Krallmann-Wenzel, U.; Ehlers, S. Trivalent &-D-mannoside clusters as inhibitors of type-1 fimbriae-mediated adhesion of Escherichia coli: structural variation and biotinylation. J. Chem. Soc., Perkin Trans. 1 2001, 823-831.

Received February 25, 2003 Accepted July 23, 2003

Downloaded by [University of California, San Diego] at 04:38 12 June 2015

577